Cargando…

FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment

Disclosure: A.M. Sawka: None. S. Ghai: None. L. Rotstein: None. J.C. Irish: None. J.D. Pasternak: None. P.J. Gullane: None. E. Monteiro: None. J. Su: None. W. Xu: None. J.M. Jones: None. A. Gafni: None. N.N. Baxter: None. D.P. Goldstein: None. Background: It is important to understand the fears of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawka, Anna M, Ghai, Sangeet, Rotstein, Lorne, Irish, Jonathan C, Pasternak, Jesse D, Gullane, Patrick J, Monteiro, Eric, Su, Jie, Xu, Wei, Jones, Jennifer M, Gafni, Amiram, Baxter, Nancy N, Goldstein, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554702/
http://dx.doi.org/10.1210/jendso/bvad114.1870
_version_ 1785116475969765376
author Sawka, Anna M
Ghai, Sangeet
Rotstein, Lorne
Irish, Jonathan C
Pasternak, Jesse D
Gullane, Patrick J
Monteiro, Eric
Su, Jie
Xu, Wei
Jones, Jennifer M
Gafni, Amiram
Baxter, Nancy N
Goldstein, David P
author_facet Sawka, Anna M
Ghai, Sangeet
Rotstein, Lorne
Irish, Jonathan C
Pasternak, Jesse D
Gullane, Patrick J
Monteiro, Eric
Su, Jie
Xu, Wei
Jones, Jennifer M
Gafni, Amiram
Baxter, Nancy N
Goldstein, David P
author_sort Sawka, Anna M
collection PubMed
description Disclosure: A.M. Sawka: None. S. Ghai: None. L. Rotstein: None. J.C. Irish: None. J.D. Pasternak: None. P.J. Gullane: None. E. Monteiro: None. J. Su: None. W. Xu: None. J.M. Jones: None. A. Gafni: None. N.N. Baxter: None. D.P. Goldstein: None. Background: It is important to understand the fears of individuals newly diagnosed with papillary thyroid cancer (PTC) to optimize patient counselling and supportive care. Our aim was to explore for potential gender differences in fears experienced by individuals with PTC prior to treatment. Methods: In this prospective study conducted in Toronto, Canada, we enrolled patients with untreated small low risk PTC (< 2 cm in maximal diameter), and offered them the choice of thyroidectomy or active surveillance (Clinicaltrials.gov: NCT03271892). All participants had a surgical consultation prior to assessment. Participants completed Fear of Progression (Short Form) and Fear of Surgery (referring to thyroidectomy) questionnaires, prior to making a decision on PTC management. We also evaluated potential fears that were specific to thyroidectomy (e.g. voice change, thyroid hormone treatment, hypocalcemia, and scar appearance). Total fear scores were calculated for the respective questionnaires. We compared data collected in women and men and explored for factors associated with respective fears using multivariable linear regression analyses. Results: We included 153 women of mean age 50.7 years (standard deviation, SD 15.0) and 47 men of mean age 56.3 years (SD 13.8). There were no significant differences in primary tumor size, marital status, education, parental status, or employment status of women and men. On a scale of 5 to 60 (where 60 is the worst), the mean total fear of disease progression questionnaire score was 26.2 (SD 9.7) in women and 23.0 (SD 9.2) in men (p=0.031). On a scale of 0 to 80 (80 being the worst), the mean total surgical fear questionnaire score was 34.1 (SD 20.3) in women and 22.0 (17.9) in men (p<0.001). Women were also more fearful than men about potential postoperative change in voice (p=0.001), hypocalcemia (p=0.003), and scar appearance (p<0.001). In respective multivariable linear regression analyses, age group (p<0.001) was independently inversely associated with fear of disease progression, whereas being a woman was independently associated with surgical fear (p=0.002). Conclusions: Demographic factors appear to be associated with fears of low-risk PTC patients who are considering primary disease management. Younger patients may have a greater fear of disease progression while women may have a greater fear of the morbidity from thyroidectomy. These factors may be important to consider in patient counselling. Presentation: Friday, June 16, 2023
format Online
Article
Text
id pubmed-10554702
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105547022023-10-06 FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment Sawka, Anna M Ghai, Sangeet Rotstein, Lorne Irish, Jonathan C Pasternak, Jesse D Gullane, Patrick J Monteiro, Eric Su, Jie Xu, Wei Jones, Jennifer M Gafni, Amiram Baxter, Nancy N Goldstein, David P J Endocr Soc Thyroid Disclosure: A.M. Sawka: None. S. Ghai: None. L. Rotstein: None. J.C. Irish: None. J.D. Pasternak: None. P.J. Gullane: None. E. Monteiro: None. J. Su: None. W. Xu: None. J.M. Jones: None. A. Gafni: None. N.N. Baxter: None. D.P. Goldstein: None. Background: It is important to understand the fears of individuals newly diagnosed with papillary thyroid cancer (PTC) to optimize patient counselling and supportive care. Our aim was to explore for potential gender differences in fears experienced by individuals with PTC prior to treatment. Methods: In this prospective study conducted in Toronto, Canada, we enrolled patients with untreated small low risk PTC (< 2 cm in maximal diameter), and offered them the choice of thyroidectomy or active surveillance (Clinicaltrials.gov: NCT03271892). All participants had a surgical consultation prior to assessment. Participants completed Fear of Progression (Short Form) and Fear of Surgery (referring to thyroidectomy) questionnaires, prior to making a decision on PTC management. We also evaluated potential fears that were specific to thyroidectomy (e.g. voice change, thyroid hormone treatment, hypocalcemia, and scar appearance). Total fear scores were calculated for the respective questionnaires. We compared data collected in women and men and explored for factors associated with respective fears using multivariable linear regression analyses. Results: We included 153 women of mean age 50.7 years (standard deviation, SD 15.0) and 47 men of mean age 56.3 years (SD 13.8). There were no significant differences in primary tumor size, marital status, education, parental status, or employment status of women and men. On a scale of 5 to 60 (where 60 is the worst), the mean total fear of disease progression questionnaire score was 26.2 (SD 9.7) in women and 23.0 (SD 9.2) in men (p=0.031). On a scale of 0 to 80 (80 being the worst), the mean total surgical fear questionnaire score was 34.1 (SD 20.3) in women and 22.0 (17.9) in men (p<0.001). Women were also more fearful than men about potential postoperative change in voice (p=0.001), hypocalcemia (p=0.003), and scar appearance (p<0.001). In respective multivariable linear regression analyses, age group (p<0.001) was independently inversely associated with fear of disease progression, whereas being a woman was independently associated with surgical fear (p=0.002). Conclusions: Demographic factors appear to be associated with fears of low-risk PTC patients who are considering primary disease management. Younger patients may have a greater fear of disease progression while women may have a greater fear of the morbidity from thyroidectomy. These factors may be important to consider in patient counselling. Presentation: Friday, June 16, 2023 Oxford University Press 2023-10-05 /pmc/articles/PMC10554702/ http://dx.doi.org/10.1210/jendso/bvad114.1870 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
Sawka, Anna M
Ghai, Sangeet
Rotstein, Lorne
Irish, Jonathan C
Pasternak, Jesse D
Gullane, Patrick J
Monteiro, Eric
Su, Jie
Xu, Wei
Jones, Jennifer M
Gafni, Amiram
Baxter, Nancy N
Goldstein, David P
FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title_full FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title_fullStr FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title_full_unstemmed FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title_short FRI525 Gender Differences In Fears Related To Low Risk Papillary Thyroid Cancer And Its Treatment
title_sort fri525 gender differences in fears related to low risk papillary thyroid cancer and its treatment
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554702/
http://dx.doi.org/10.1210/jendso/bvad114.1870
work_keys_str_mv AT sawkaannam fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT ghaisangeet fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT rotsteinlorne fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT irishjonathanc fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT pasternakjessed fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT gullanepatrickj fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT monteiroeric fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT sujie fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT xuwei fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT jonesjenniferm fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT gafniamiram fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT baxternancyn fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment
AT goldsteindavidp fri525genderdifferencesinfearsrelatedtolowriskpapillarythyroidcanceranditstreatment